219 - Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products

10/5/2019

10:30 AM - 11:45 AM

Room: Walter E. Washington Convention Center, Salon ABC

MOC Credit: Maximum of 1.25 hours of MOC Credit
CME Credit: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE Credit: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-19-409-L01-P

Co-organized with the Centers for Disease Control and Prevention

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the epidemiology and molecular features of RSV A and B in the U.S. and globally
discuss correlates of protection in children and adults
describe RSV disease severity and mortalitiy

Presentations:

10:30 AM - 10:55 AM
1924 - Approaches to Measuring RSV Disease Burden (and Why it Matters)
Gayle Langley, MD, MPH – Centers for Disease Control and Prevention
10:55 AM - 11:20 AM
1925 - RSV A, B and Molecular Features in the U.S. and throughout the World
Helen Y. Chu, MD MPH – University of Washington
11:20 AM - 11:45 AM
1926 - Updates on Correlates of Protection among Children and Adults
Edward E. Walsh, MD – University of Rochester

Moderator(s)

Inger Damon, MD, PhD

Director Division of High Consequence Pathogens and Pathology
Centers for Disease Control and Prevention
Atlanta, Georgia

Disclosure: Nothing to disclose
Susan Gerber, MD

Chief, Respiratory Viruses Branch, Division of Viral Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Disclosure: Nothing to disclose

Speaker(s)

Helen Chu, MD MPH

Assistant Professor
University of Washington
Seattle, WA

Disclosure: Merck: Advisory Board
Sanofi Pasteur: Research Grant
GL

Gayle Langley, MD, MPH

Medical epidemiologist
Centers for Disease Control and Prevention
Atlanta, GA

Disclosure: Nothing to disclose
Edward Walsh, MD

Professor of Medicine
University of Rochester
Rochester, New York

Disclosure: Janssen Pharm: Consultant, no financial payment however
Pfizer: Research Grant